tiagabine (Gabitril)
Jump to navigation
Jump to search
Indications
- adjunctive treatment of partial seizures
- OFF LABEL use for migraine, bilar disorder
Dosage
- start 4 mg PO QD
- increase by increments of 4 mg
- wait one week prior to 1st dose increase; thereafter may increase dose daily
- maximum dose 32 mg
- higher doses should be given in divided doses BID-QID
Tabs: 4, 12, 16, 20 mg
Pharmacokinetics
- protein binding 96%
- 1/2life 6.7 hours
- elimination: 25% in urine, 63% in feces
Adverse effects
- all dose-related
- CNS: -dizziness, headache, somnolence, CNS depression, memory impairment, ataxia, seizures[2][3]
- abnormal vision, deteriorating color vision
- tremor
- nausea
Laboratory
Mechanism of action
- may inhibit reuptake of GABA by presynaptic terminals
More general terms
References
- ↑ Geriatric Dosage Handbook, 6th edition, Selma et al eds, Lexi-Comp, Cleveland, 2001
- ↑ 2.0 2.1 FDA Medwatch http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#Gabitril
- ↑ 3.0 3.1 Prescriber's Letter 12(4): 2005 FDA Public Health Advisory Seizures in Patients without Epilepsy Being Treated with Gabitril (tiagabine) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210406&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 15, American College of Physicians, Philadelphia 2009